BioSpace News Archive

Abivax SA announces that the first patient has been enrolled in the US into its global phase 3 clinical program with product candidate obefazimod for the treatment of moderate to severe ulcerative colitis.

Fresenius Kabi announced the successful smart pump interoperability of its Ivenix Infusion System at Fort HealthCare, a regional health care provider in Wisconsin.

BiondVax Pharmaceuticals Ltd. announced that Joshua Phillipson, BiondVax’s Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, has scheduled the release of its 2022 third quarter results for Tuesday, November 1, 2022 before the market opens.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today reported financial results for the second quarter ended June 30, 2022.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced an update from the ongoing global Phase 1 KN-8701 trial evaluating KIN-2787, an investigational pan-RAF inhibitor, in patients with BRAF-altered solid tumors and/or who have NRAS mutant melanoma.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the H.C. Wainwright 6th Annual NASH Virtual Investor Conference on Monday, October 17, 2022, at 12:00 p.m. E.T.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research, is scheduled to present at the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on Tuesday, October 18, at 10:30 a.m. PT / 1:30 p.m. ET.

Ambrx Biopharma Inc. announced the company will host a corporate update conference call and live webcast on October 18, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time, to discuss the company’s strategic review of its development pipeline.

Avidity Biosciences, Inc. (Nasdaq: RNA) today announced the Phase 1/2 EXPLORE44™ clinical trial of AOC 1044 in healthy volunteers and participants with Duchenne muscular dystrophy (DMD), a rare, genetic condition that is characterized by progressive muscle damage and weakness.